Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy

Leuk Lymphoma. 2016;57(1):34-8. doi: 10.3109/10428194.2015.1040012. Epub 2015 May 12.

Abstract

Primary cutaneous B cell lymphomas (PCBCL) are rare; although data on outcomes and treatment are limited, traditionally they have been treated with radiation doses in excess of 24 Gy. We retrospectively identified and reviewed all cases of PCBCL treated at our institution from 2002-2014. Thirty-nine patients with PCBCL (42 lesions) were identified. Radiation was the only treatment for most patients. All lesions had a complete response and none had in-field failures; seven patients had out-of-field relapses, three of which were salvaged with radiation therapy. No differences in PFS or OS were found for patients given low-dose (≤ 12 Gy) versus high-dose (> 12 Gy) radiation. PCBCL is an indolent entity with a long clinical course and excellent response to radiation therapy and successful salvage of recurrent disease, even when doses are as low as 4 Gy. Given the above findings, we recommend the initial use of low-dose irradiation for PCBCL.

Keywords: B cell; follicle center; marginal zone; radiation therapy; skin lymphoma.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Lymphoma, B-Cell / diagnosis*
  • Lymphoma, B-Cell / mortality
  • Lymphoma, B-Cell / radiotherapy*
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Radiotherapy Dosage
  • Retrospective Studies
  • Skin Neoplasms / diagnosis*
  • Skin Neoplasms / mortality
  • Skin Neoplasms / radiotherapy*
  • Treatment Outcome
  • Young Adult